Evidence map›Paper›PMID 38882060›Full record

ReviewFrontiers in cell and developmental biology2024

Molecular and therapeutic advancements in Capicua (

Rovingaile Kriska M Ponce, Cuyler Luck, Ross A Okimoto

Abstract readReview
In one paragraph

Review in Frontiers in cell and developmental biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Clinical case reports · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. ThebioRxiv : the preprint server for biology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rovingaile Kriska M PonceBoston University Chobanian and Avedisian School of Medicine, Boston, MA, United States.
Cuyler LuckDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.
Ross A OkimotoDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.

Funding

Restorative practice in repairing harm and promoting safe and inclusive practices in the laboratory.T32GM136547 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Adrian Erlebacher · 2020 to 2026
$4.5M
Therapeutic degradation of Capicua (CIC) fused oncoproteins in undifferentiated sarcomasR37CA255453 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Ross Okimoto · 2021 to 2026
$2.7M
NCI NIH HHS R37 CA255453NIGMS NIH HHS T32 GM136547
6 · The paper itself

Abstract

Capicua (

Indexed as

Capicua (CIC)CICCIC-DUX4CIC-DUX sarcomasCIC-NUTM1 sarcomasCIC-rearranged sarcoma

Identifiers

PMID38882060
PMCPMC11176417

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.